Results 121 to 130 of about 2,733,176 (326)

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine   +10 more
wiley   +1 more source

Practical challenges in data‐driven interpolation: Dealing with noise, enforcing stability, and computing realizations

open access: yesInternational Journal of Adaptive Control and Signal Processing, EarlyView., 2023
Summary In this contribution, we propose a detailed study of interpolation‐based data‐driven methods that are of relevance in the model reduction and also in the systems and control communities. The data are given by samples of the transfer function of the underlying (unknown) model, that is, we analyze frequency‐response data.
Quirin Aumann, Ion Victor Gosea
wiley   +1 more source

A Lorentz variant theory that passes fundamental tests of special relativity and makes diverging, testable but as of yet untested predictions [version 2; peer review: 2 approved]

open access: yesF1000Research
Background Tests of special relativity have been conducted over the past century with increasing accuracy and none have showed violations of Lorentz invariance.
Daniël Bischoff van Heemskerck
doaj  

Generalised Einstein mass-variation formulae: I Subluminal relative frame velocities

open access: yesResults in Physics, 2016
Much of the formalism in special relativity is intimately bound up with Einstein’s formula for the variation of mass m with its velocity v, namely m(v)=m0∗[1-(v/c)2]-1/2, where m is the mass, v the velocity, c denotes the speed of light and m0∗ denotes ...
James M. Hill, Barry J. Cox
doaj  

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Special Relativity

open access: yesThe Ideas of Particle Physics, 2019
Yury Deshko
semanticscholar   +2 more sources

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

open access: yesMolecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy